...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** BETonMACE Trial is Fully Enrolled and Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: I would have thought we'd see more volume....

As Bear just noted, there was a great run prior to the AGM, so a retrace is not unexpected.

I also think the clarity and informative nature of the AGM is a double-edged sword. It really clarified a lot of questions from SSRA to # of events to the top line data reporting timeline.  

On the other hand, while positive, it likely removed most catalysts and thus the stock IMHO can easily drift for the next couple months until people start to place their final bets on the top line data (which may not be fully informative). Of course, mainstream media or some nice analyst reports etc or other surprise (zenith sale would likely provide RVX stock price catalyst) can occur. So personally, I am going to try and not get to caught up on the day to day sp the next couple months. Hope I am wrong.


New Message
Please login to post a reply